Dr. Levy on Molecular Drivers in NSCLC

Benjamin P. Levy, MD
Published: Thursday, Nov 14, 2019



Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the identification of molecular drivers in non­–small cell lung cancer (NSCLC).
 
Multiple actionable mutations have been identified in lung cancer, including EGFR, ALK, RET, ROS1, BRAF, HER2, MET exon 14 skipping, NTRK, and KRAS G12C. As such, there are a number of approved or investigational agents for patients with these mutations, says Levy.
 
Due to the growing number of targets that are emerging, all patients with advanced lung cancer should undergo comprehensive genomic profiling with next-generation sequencing, concludes Levy.
 
SELECTED
LANGUAGE


Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the identification of molecular drivers in non­–small cell lung cancer (NSCLC).
 
Multiple actionable mutations have been identified in lung cancer, including EGFR, ALK, RET, ROS1, BRAF, HER2, MET exon 14 skipping, NTRK, and KRAS G12C. As such, there are a number of approved or investigational agents for patients with these mutations, says Levy.
 
Due to the growing number of targets that are emerging, all patients with advanced lung cancer should undergo comprehensive genomic profiling with next-generation sequencing, concludes Levy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x